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1. Introduction 
The consequences of uncontrolled diabetes mellitus during pregnancy are severe for both 
mother and fetus. The risk of congenital malformations among infants of diabetic mothers is 
related to the quality of the diabetic control (Allen et al., 2007; American Diabetes 
Association [ADA], 2004). In diabetic pregnancy, unsatisfactory glycemic control at the 
moment of diagnosis or delivery of care was associated with an increased risk of anomalies 
(Allen et al., 2007; Schaefer-Graf at al., 2000). The most common anomalies involve the 
cardiac, musculoskeletal, and central nervous systems (Sheffield at al., 2002). Despite this 
knowledge, it has been disappointing that so few diabetic women receive preconception 
counseling, plan their pregnancies or are early referred to tertiary centers (American 
Diabetes Association [ADA], 2004; Reis at al., 2010a). Considering this reality, it is important 
to study second trimester markers of congenital cardiopathies, in order to decrease fetal 
morbidity and mortality, at birth. 
2. Congenital cardiopathies and diabetes mellitus  
If maternal hyperglycemia is present during organogenesis there is an increased risk of 
congenital anomalies and miscarriage (American Diabetes Association [ADA], 2004). 
Experimental studies suggest that hyperglycemia is the major teratogen in diabetic 
pregnancies, but other diabetes-related factors may also affect fetal outcomes (Aberg at al., 
2001; Buchanan & Kjos, 1999; Leonard et al., 1989; Ren et al., 2011). It is a fact that an 
uncontrolled diabetes mellitus in early gestation is associated with a teratogenic effect, 
causing primary cardiogenesis defects. Most types of cardiac structural lesions have been 
associated with diabetes mellitus, ranging from small septal defects to major heart disease 
(Sekhavat et al., 2010; Abu-Sulaiman & Subaih, 2004). 
The exact teratogenic mechanism of maternal diabetes is not fully defined and is likely 
multifactorial (Hornberger, 2006; Kumar et al., 2007). Diabetes mellitus affects the fetal heart 
both structurally and functionally. In late gestation, it causes a unique form of hypertrophic 
cardiomyopathy (Ren et al., 2011; Hornberger, 2006; Chaudhari et al., 2008; Russell et al., 
2008), illustrated at Fig. 1. Cardiomegaly is a common finding in stillborn infants of mothers 
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with diabetes mellitus and may contribute to the risk of fetal death in these pregnancies 
(Russell et al., 2008). Hypertrophic cardiomyopathy observed in the infant of the diabetic 
mother is characterized by thickening of the interventricular septum, and to a lesser extent 
the ventricular free walls (Hornberger, 2006).  The presence of this pathology whether is 
associated with fetal hyperinsulinaemia and general somatic growth in maternal diabetes 
(Buchanan & Kjos, 1999; Ren et al., 2011). But, the wide variety of cardiac abnormalities 
suggests a complex pathogenesis. Experimental study proposed that the down-regulation of 
genes involved in development of cardiac neural crest could contribute to the pathogenesis 
of maternal diabetes-induced congenital heart defects (Kumar et al., 2007).  
 
 
Fig. 1. Image of fetal ultrasonography: hypertrophic cardiomyopathy associated with 
Diabetes Mellitus 
3. The strategies for prevention and management of the cardiac teratogenic 
effects in diabetes mellitus 
The prevalence of pregestational diabetes among women early in their reproductive years is 
increasing. Thus, identifying women with diabetes is important because the diagnosis and 
appropriate therapy can decrease fetal and maternal morbidity (Crowtherl et al., 2005). 
Preconceptional evaluation and counseling of women with diabetes mellitus (type 1 or type 
2) is fundamental point to minimize the risk to the fetus and mother. It is known that 
pregnancies in diabetes mellitus women should be planned, but that condition was not so 
frequent (American Diabetes Association [ADA], 2004; Reis at al., 2010a; Chaudhari et al., 
2008). Unplanned pregnancy occurs in about two-thirds of women with diabetes leading to 
a persistent excess of malformations in their infants (American Diabetes Association [ADA], 
2004).  
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Given the increased risk of congenital abnormalities among infants of diabetic mothers, an 
appropriate biochemical, ultrasonographic screening process and a detailed evaluation of 
fetal cardiac structure should be offered to all pregnant women with diabetes (Allen et al., 
2007). A prenatal cardiac screening is purposed to identify defects that may require further 
evaluation and treatment, and to provide appropriate counselling to the family in a timely 
manner (American Diabetes Association [ADA], 2004; Sekhavat et al., 2010). Detailed fetal 
anatomic surveys in the early second trimester are common practice and typically include 
examination of both four-chamber and outflow tract views of the fetal heart. 
The occurrence of congenital cardiopathies at echocardiography in fetuses whose mothers 
had preexisting diabetes mellitus was investigated in our tertiary university medical center 
(Reis at al., 2010a, 2010b). The most frequent conditions were hypertrophic cardiomyopathy 
(70%), pericardial effusion (15%), followed by intermittent or persistent bradycardia (15%). 
The most frequent structural congenital cardiopathies at echocardiography was 
interventricular communication (85.7%) associated or not to another heart malformations 
(Fig. 2). Functional findings at echocardiography were significantly more frequent among 
the poorly-controlled diabetic pregnancies.  
 
 
Fig. 2. Image of fetal ultrasonography: interventricular comunication associated with 
Diabetes Mellitus  
In other reports, the malformations found in neonates, born of insulin-dependent diabetes 
mellitus gestations, included endocardial cushion defects, persistent truncus arteriosus and 
ventricular septal defects which appear to result from aberrant cardiac neural crest 
development (Sekhavat et al., 2010; Abu-Sulaiman & Subaih, 2004; Hornberger, 2006; Kumar 
et al., 2007; Russell et al., 2008). Hypertrophic cardiomyopathy was observed in 38% of 
neonates from insulin-dependent diabetes mellitus pregnant women, mainly hypertrophy of 
the interventricular septum (Abu-Sulaiman & Subaih, 2004).  
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4. The fructosamine level as a late marker (beyond the first trimester) for 
congenital cardiopathies 
The measurement of glycated hemoglobin (HbAlc) and serum fructosamine in order to 
assess the recent glycemic control of diabetic patients has become well established. Maternal 
HbAlc at the beginning of pregnancy and maternal age at the onset of diabetes were 
associated with congenital malformations (Aberg at al., 2001).  
Fructosamines are keto-amines formed by a non-enzymatic reaction between glucose and a 
protein (60-70% of which is glycosylated with albumin in serum), depending upon the 
severity and the duration of the hyperglycemia. Therefore, serum fructosamine directly 
reflects the dynamics of blood glucose concentration and correlates significantly with the 
mean plasma glucose levels from the preceding 1 to 3 weeks (Roberts et al., 1988; 
Weerasekera, 2000; Jenkins et al., 2007). Fructosamine testing has been available since the 
1980s. Both fructosamine and HbA1c are used primarily as monitoring tools to help 
diabetics control their blood sugar, but the A1C test is much more popular and more widely 
accepted. However, the American Diabetes Association recognizes both tests and says that 
fructosamine may be useful in situations where the A1C cannot be reliably measured 
(Goldstein et al., 2004). In addition, the measurement of fructosamine can be a helpful 
adjunct to HbA1c glycaemic control monitoring during pregnancy (Chaudry et al., 2007). 
The role of fructosamine levels as a teratogenic marker is less studied. 
Fetuses presenting a normal and abnormal echocardiography were compared using plasma 
fructosamine level means (Reis at al., 2010a).  An association between congenital 
cardiopathies at echocardiography (functional and structural including isolated 
hypertrophic cardiomiopathy) and types of diabete mellitus (insulin-depending or not), was 
evaluated. An abnormal plasma fructosamine level at 20.4±8.0 weeks of gestation was 
associated with congenital cardiopathies at echocardiography, whether or not the cardiac 
embryogenesis happened in the first trimester. The congenital cardiopathies at 
echocardiography odds ratio was 9.6 (95% CI: 2.8 – 33.7) for abnormal plasma fructosamine 
(≥2.68mmol/L) and 10.9 (95% CI: 2.7 – 45.2) when adjusted for maternal age and insulin 
usage. There was also an increased chance (3.1, 95% CI: 1.1 - 8.8) of fetal heart anomaly with 
insulin usage, but only when evaluated individually by crude odds ratio.  
In many underdeveloped countries, women do not have access or do not attend medical 
care early in pregnancy (Reis at al., 2010a, 2010b). Therefore, they are especially subject to 
the teratogenic effects of hyperglycemia.  Analyzing results of our universitary referral 
center, it was disappointing that so few diabetic women receive preconception counseling 
and plan their pregnancies (Reis at al., 2010a). Therefore, considering this reality, without 
HbA1c early values, it was important to determine the correlation between fructosamine 
maternal levels and fetal malformations.  
Based on our previous study, abnormal maternal fructosamine levels, even at the second 
trimester of pregnancy, predicts a high risk of fetal cardiac anomalies (Reis at al., 2010a). In 
this way, a fetal echocardiographic exam should be, routinely, performed in all diabetic 
mothers whose fructosamine levels are above 2.23 mmol/L  (Reis et al., 2010b).  
This recommendation was based on the significant capacity of maternal fructosamine levels to 
predict fetal heart anomaly in diabetic patients (Area Under Curve: 0.78 p-valor <0.0001), as 
shown in Fig. 3. However, different cut-off values from which fructosamine could indicate 
these malformations and they should be cautiously defined and discussed as shown in Table 1. 
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Fig. 3. Receiver–operating characteristics (ROC) curve for prediction of congenital 
cardiopathies at echocardiography for fetuses whose mothers had preexisting diabetes 
mellitus (n=65). AUC 0.78 (95% CI, 0.66–0.89), from: Reis et al., 2010 
 
Cut-off  points 
(maternal plasmatic levels of 
fructosamine ) 
Sensitivity Specificity 
False 
negative 
Positive 
Likelihood ratio 
2.23 mmol/L 88.2% 54.8% 11.8% 2.0 
2.68 mmol/L 58.8% 87.1% 41.2% 4.6 
2.90 mmol/L 44.1% 96.8% 55.9% 13.7 
Table 1. Accuracy of the maternal fructosamine levels for the prediction of fetal cardiac 
anomalies in gestations complicated by diabetes mellitus. Reference: Reis et al., 2010b 
If it is considered the cut-off value of fructosamine recommended for our local population 
(2.68mmol\L), this test will have a good specificity (87.1%) but a low sensitivity (58.8%), 
with a false negative rate of 41.2%.  Even though, for an abnormal exam, the risk of fetal 
cardiac anomaly is increased 4.6-fold.  If it is considered the cut-off value recommended by 
the manufacturer of the test  (2.90mmol/L), the exam will have a high specificity (96.8%) but 
a low sensitivity (44.1%)  with a false negative rate of 55.9%. In this case, for an abnormal 
test, the risk of fetal cardiac defects would be increased 13.7-fold. Finally considering the use 
of a cut-off  point of 2.23mmol\L, the test will show a low specificity (54.8%) but a high 
sensitivity (88.2%), with a false negative rate of 11.8%. Thus, the cut-off point of 2.23 
mmol/L is better than the other values tested, since it has the greatest sensitivity and lowest 
false negative rate among them. 
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5. Conclusions 
Abnormal echocardiographic findings were associated with the first maternal plasma 
fructosamine levels in referral pregnancies complicated by diabetes mellitus. Hyperglycemia 
seems to be the most important determinant of these risks. Many pregnant diabetic women 
are referred at a late stage to a tertiary level of care. At this context, an abnormal plasma 
fructosamine level increases the chances of abnormalities at fetal echocardiography. It is 
possible to use a second trimester plasma fructosamine level to refer women with 
pregestational diabetes mellitus to a center of maternal-fetal medicine in order to offer them 
an appropriated assistance at birth. These findings are important for the management of 
women with diabetes mellitus and late prenatal care. 
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